News
Pfizer's Tukysa greenlit for earlier use in breast cancer
Pfizer gets FDA approval for maintenance use of its oral HER2 inhibitor Tukysa in breast cancer, which it hopes will unlock renewed sales growth.
News
PhRMA sues Trump administration over GLOBE rebate scheme
PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation pricing in Medicare Part B in a US district court.
News
Rhapsido is first drug cleared for chronic hives disorder SD
Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.
News
European biotech leaders say optimism is returning
Senior figures in European biopharma think dealmaking and M&A will increase in the region, and could be helped by US policy uncertainties.
News
Click claims FDA okay for first-in-class schizophrenia DTx
Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
